Literature DB >> 28483952

Multicenter Study of Outcomes with Ceftazidime-Avibactam in Patients with Carbapenem-Resistant Enterobacteriaceae Infections.

Madeline King1, Emily Heil2, Safia Kuriakose3, Tiffany Bias4, Vanthida Huang5, Claudine El-Beyrouty6, Dorothy McCoy7, Jon Hiles8, Lynette Richards3, Julianne Gardner9, Nicole Harrington9, Kenneth Biason3, Jason C Gallagher10.   

Abstract

Ceftazidime-avibactam is a novel cephalosporin-beta-lactamase inhibitor combination that is active against many carbapenem-resistant Enterobacteriaceae (CRE). We describe a retrospective chart review for 60 patients who received ceftazidime-avibactam for a CRE infection. In-hospital mortality was 32%, 53% of patients had microbiological cure, and 65% had clinical success. In this severely ill population with CRE infections, ceftazidime-avibactam was an appropriate option.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  antibiotic resistance; beta-lactamases; carbapenemase

Mesh：

Substances：

Year:  2017        PMID： 28483952      PMCID： PMC5487633          DOI： 10.1128/AAC.00449-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

Review 2.  Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes.

Authors:  David van Duin; Keith S Kaye; Elizabeth A Neuner; Robert A Bonomo
Journal:  Diagn Microbiol Infect Dis       Date:  2013-01-03       Impact factor: 2.803

3.  Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens.

Authors:  Zubair A Qureshi; David L Paterson; Brian A Potoski; Mary C Kilayko; Gabriel Sandovsky; Emilia Sordillo; Bruce Polsky; Jennifer M Adams-Haduch; Yohei Doi
Journal:  Antimicrob Agents Chemother       Date:  2012-01-17       Impact factor: 5.191

4.  Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections.

Authors:  Ryan K Shields; Brian A Potoski; Ghady Haidar; Binghua Hao; Yohei Doi; Liang Chen; Ellen G Press; Barry N Kreiswirth; Cornelius J Clancy; M Hong Nguyen
Journal:  Clin Infect Dis       Date:  2016-09-13       Impact factor: 9.079

5.  Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial.

Authors:  Christopher Lucasti; Irinel Popescu; Mayakonda K Ramesh; Joy Lipka; Carole Sable
Journal:  J Antimicrob Chemother       Date:  2013-02-07       Impact factor: 5.790

6.  International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial Infections.

Authors:  David L Paterson; Wen-Chien Ko; Anne Von Gottberg; Sunita Mohapatra; Jose Maria Casellas; Herman Goossens; Lutfiye Mulazimoglu; Gordon Trenholme; Keith P Klugman; Robert A Bonomo; Louis B Rice; Marilyn M Wagener; Joseph G McCormack; Victor L Yu
Journal:  Ann Intern Med       Date:  2004-01-06       Impact factor: 25.391

Review 7.  Sepsis: pathophysiology and clinical management.

Authors:  Jeffrey E Gotts; Michael A Matthay
Journal:  BMJ       Date:  2016-05-23

8.  Deaths attributable to carbapenem-resistant Enterobacteriaceae infections.

Authors:  Matthew E Falagas; Giannoula S Tansarli; Drosos E Karageorgopoulos; Konstantinos Z Vardakas
Journal:  Emerg Infect Dis       Date:  2014-07       Impact factor: 6.883

9.  Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program.

Authors:  John E Mazuski; Leanne B Gasink; Jon Armstrong; Helen Broadhurst; Greg G Stone; Douglas Rank; Lily Llorens; Paul Newell; Jan Pachl
Journal:  Clin Infect Dis       Date:  2016-03-08       Impact factor: 9.079

Review 10.  Ceftazidime-avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections.

Authors:  Philippe Lagacé-Wiens; Andrew Walkty; James A Karlowsky
Journal:  Core Evid       Date:  2014-01-24
  10 in total
  26 in total

Review 1.  Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Children.

Authors:  Kathleen Chiotos; Molly Hayes; Jeffrey S Gerber; Pranita D Tamma
Journal:  J Pediatric Infect Dis Soc       Date:  2020-02-28       Impact factor: 3.164

Review 2.  [New β‑lactam antibiotics and β‑lactamase inhibitors against multidrug-resistant Gram-negative bacteria].

Authors:  Alexander Mischnik; Christoph Lübbert; Nico T Mutters
Journal:  Internist (Berl)       Date:  2018-12       Impact factor: 0.743

Review 3.  Carbapenem-Resistant Enterobacteriaceae in Solid Organ Transplantation: Management Principles.

Authors:  Olivia Smibert; Michael J Satlin; Anoma Nellore; Anton Y Peleg
Journal:  Curr Infect Dis Rep       Date:  2019-06-10       Impact factor: 3.725

Review 4.  The Epidemiology, Evolution, and Treatment of KPC-Producing Organisms.

Authors:  Ann Marie Porreca; Kaede V Sullivan; Jason C Gallagher
Journal:  Curr Infect Dis Rep       Date:  2018-05-05       Impact factor: 3.725

Review 5.  Recognizing and Overcoming Resistance to New Beta-Lactam/Beta-Lactamase Inhibitor Combinations.

Authors:  Stephanie Ho; Lynn Nguyen; Trang Trinh; Conan MacDougall
Journal:  Curr Infect Dis Rep       Date:  2019-09-09       Impact factor: 3.725

6.  Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections.

Authors:  Ryan K Shields; M Hong Nguyen; Liang Chen; Ellen G Press; Barry N Kreiswirth; Cornelius J Clancy
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

Review 7.  Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.

Authors:  Jesús Rodríguez-Baño; Belén Gutiérrez-Gutiérrez; Isabel Machuca; Alvaro Pascual
Journal:  Clin Microbiol Rev       Date:  2018-02-14       Impact factor: 26.132

Review 8.  Treatment Options for Carbapenem- Resistant Gram-Negative Infections.

Authors:  Moritz Fritzenwanker; Can Imirzalioglu; Susanne Herold; Florian M Wagenlehner; Klaus-Peter Zimmer; Trinad Chakraborty
Journal:  Dtsch Arztebl Int       Date:  2018-05-21       Impact factor: 5.594

9.  Antibacterial Activity of Human Simulated Epithelial Lining Fluid Concentrations of Ceftazidime-Avibactam Alone or in Combination with Amikacin Inhale (BAY41-6551) against Carbapenem-Resistant Pseudomonas aeruginosa and Klebsiella pneumoniae.

Authors:  Safa S Almarzoky Abuhussain; Joseph L Kuti; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

Review 10.  Pharmacological aspects and spectrum of action of ceftazidime-avibactam: a systematic review.

Authors:  Felipe Francisco Tuon; Jaime L Rocha; Marcelo R Formigoni-Pinto
Journal:  Infection       Date:  2017-11-07       Impact factor: 3.553
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.